Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for HemophiliaLabiotech.eu (blog)uniQure is getting ready to start a Phase III clinical trial in 2018 with a new version of its gene therapy for hemophilia B. uniQure has officially lau… Continue reading
Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for HemophiliaLabiotech.eu (blog)uniQure is getting ready to start a Phase III clinical trial in 2018 with a new version of its gene therapy for hemophilia B. uniQure has officially lau… Continue reading
Life Sciences Intellectual Property ReviewBroad and DuPont yield CRISPR licensing deal in agricultureLife Sciences Intellectual Property ReviewThe Broad Institute of Harvard and MIT has signed a patent licensing deal with DuPont Pioneer to provide … Continue reading
|
UniQure, chasing Spark-level FIX activity, tweaks hemophilia B gene therapy ahead of 2018 pivotal trial
FierceBiotech UniQure has modified its hemophilia B gene therapy to dial up factor IX (FIX) activity to the levels achieved by Spark Therapeutics’ rival product. The mid-development tweaks have the blessing of regulators, enabling uniQure to start a pivotal trial … |
|
FDA approves Gilead cancer gene therapy; price set at $373000
Reuters (Reuters) – U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s (GILD.O) Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. |